breast cancer

Arkin receives Ono Pharma Foundation Breakthrough Science Initiative Award

Fri Aug 31, 2018

Michelle Arkin, PhD

Michelle Arkin, PhD, has received the 2018 Breakthrough Science Initiative Award from the Ono Pharma Foundation to study a class of proteins, called 14-3-3 proteins, known to be involved in various cancers, with the ultimate goal of enabling discoveries that lead to new ways to treat cancer.

Stopping cancer in its tracks

Thu Jul 19, 2018

Cecil Fox, National Cancer Institute

Cancerous breast tissue, with normal connective tissue (pink) and cancer cells (blue).

Cancer, fundamentally, is a problem of too much growth. For decades, health care providers have tried and failed to slow tumor growth using drugs that interfere with a particular signaling pathway, called PI3K, which is known to operate in proliferating cancer cells.

UC San Francisco establishes Quantitative Biosciences Institute

Wed Mar 16, 2016

Susan Merrell

Nevan Krogan, PhD

UC San Francisco today announced the establishment of the Quantitative Biosciences Institute (QBI).

Kroetz leads new study of genetics of cancer drugs’ dose-limiting side effects

Mon Jul 27, 2015

Deanna Kroetz, PhD

Taxanes are a class of drugs widely used to treat a variety of cancers, including breast, ovarian, lung, gastric, and head and neck. But dosages are often limited by toxic side effects—most commonly damage to the body’s peripheral nerves, causing numbness, pain, and/or hyper-sensitivity—that can...

Label warnings, antibiotic measurements, cancer therapies, and smoking interventions take top honors at annual seminar

Thu May 22, 2014

Rifkind Award Winners (clockwise from upper left) Tien Ho, PharmD; Bao Dao, PharmD, MBA; Robin Corelli, PharmD; Alicia Harvey, PharmD.

Studies of improved over-the-counter acetaminophen warning labels, more accurate measurements of antibiotics in hospitalized patients, therapies for metastatic breast cancer, and methods for training pharmacy personnel to help smokers quit took top honors at the Department of Clinical Pharmacy’s...

Gartner receives NIH New Innovator Award to build complex human breast tissue

Mon Sep 30, 2013

Zev Gartner, PhD

Zev Gartner, PhD, has been named a recipient of the 2013 National Institutes of Health (NIH) Director’s New Innovator Award, which will provide his lab with up to $1.5 million in research funding over the next five years.

Study builds breast tissues to track how abnormal cells affect neighbors

Tue Oct 23, 2012

Zev Gartner, PhD

It can take just the flick of a genetic switch for breast cells to kick-start the normally well-regulated process of growth seen in puberty, pregnancy, or the menstrual cycle—or the mutation of that switch to initiate the unchecked proliferation of cancer.

Gartner to lead study on the interactions of cells in breast cancer

Tue Jan 18, 2011

Zev Gartner, PhD

Zev Gartner, PhD, a faculty member in the UCSF School of Pharmacy, will lead a US$3.2 million grant to study the interaction of different types of cells in breast cancer at its earliest stages.

Study identifies lack of information about HER2 testing practices

Fri Oct 16, 2009

Breast cancer patients might not be getting full advantage from a genetic screening test for the protein known as HER2 to help determine if the use of trastuzumab (marketed as Herceptin) is the best course of treatment for them. For patients whose breast cancer cells produce excessive amounts of...

Kroetz elected fellow of American Association of Pharmaceutical Scientists

Mon Dec 15, 2008

Deanna Kroetz, PhD, UCSF School of Pharmacy faculty member, has been elected as a fellow of the American Association of Pharmaceutical Scientists (AAPS).

Topics and Expertise: breast cancer